Indication
Recurrent WHO Grade 2 Glioma
6 clinical trials
7 products
1 drug
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 MutationsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
IvosidenibClinical trial
A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2029-05-12
Product
TMZProduct
TriapineClinical trial
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 MutationsStatus: Recruiting, Estimated PCD: 2026-12-30
Product
SelumetinibProduct
VinblastineClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Product
TipifarnibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene AlterationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Product
SelpercatinibClinical trial
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene FusionStatus: Recruiting, Estimated PCD: 2026-10-23
Product
Erdafitinib